Here is the summary for Hikal Ltd.'s financial update: **1. Financial Highlights:** Hikal's Q1 FY26 consolidated revenue hit Rs. 380 Cr, with EBITDA at Rs. 25 Cr (6.5% margin), and a net loss of Rs. 23 Cr.

Pharma revenue (Rs. 203 Cr) saw an EBIT loss due to temporary off-take deferment.

Crop protection (Rs. 178 Cr) faced margin pressure.

FY25 balance sheet shows improved operating cashflow and reduced debt. **2. Strategic Initiatives & Growth Drivers:** Pharma's Q1 was impacted by a US FDA OAI-related pause, with supplies expected from Q2. Successful GMP audits by ANVISA/PMDA at Bangalore strengthen global market access.

Animal health molecules target FY27 commercialization.

Crop protection anticipates H2 FY26 volume recovery and efficiency focus. **3. Business Developments:** Hikal is actively addressing US FDA observations, with customer audits completed.

Both pharma and crop protection CDMO segments report robust project pipelines.

Capabilities are expanding in high-potency/complex chemistry and pharma product registrations continue in regulated markets. **4. Market Position & Competitive Advantage:** Successful ANVISA/PMDA audits reinforce Hikal's strong compliance and quality commitment, enhancing its global standing.

The company maintains operational efficiency via product mix and cost discipline, crucial in competitive sectors. **5. Investor Implications:** Despite a challenging Q1, management remains confident in FY26 guidance.

Recovery is projected for Q3-Q4, driven by improved demand visibility and new product commercialization, signaling positive growth potential.